Skip to content

Released Mar 28, 2024, after the close

10-K filed Mar 28, 2024, 88 days after period end · 0000950170-24-038057

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$7.16Mderivedno prior Q4 2022 on fileno prior Q3 2023 on file
Net Income-$10.96MderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$12,551,000N/M
Operating Cash Flowderived$73,647,000N/M
Free Cash Flowderived$73,576,000N/M
Margins · derived
Operating margin-175.2%
Net margin-153.0%

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020
Revenue$7.16M——$1.04M
Net Income-$10.96M-$22.40M-$60.26M-$39.42M
EPS Diluted———-$1.11

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR